MedTrace Logo

A Study Of Different Doses Of TBC3711 In Patients With Uncontrolled High Blood Pressure Already Taking Medications For High Blood Pressure.

NCT00272961 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2013-03-05

Study results available
· View outcomes & findings →

Summary

The study was to determine the safe and effective dose of TBC3711 in patients with uncontrolled high blood pressure while already taking blood pressure medications.

Conditions

  • Resistant Hypertension

Interventions

DRUG

Placebo

placebo tablet once daily for 12 weeks

DRUG

TBC3711

10 mg tablets once daily for 10 weeks

DRUG

TBC3711

50 mg tablet once daily for 10 weeks

DRUG

TBC3711

100 mg tablet once daily for 10 weeks

DRUG

TBC3711

200 mg tablet once daily for 10 weeks

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00272961 on ClinicalTrials.gov